Patients with relapsed refractory myeloma have been subjected to a Phase I clinical trial of intravenous administration of oncolytic MV vectors expressing the human sodium iodide symporter (NIS) [150]. The gene discussed is SLC5A5; the disease is plasma cell myeloma.